CombiGene
2,92 SEK -1,35%Vær den første som følger denne virksomhed
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
COMBI
Daglig lav / høj pris
2,82 / 2,98
SEK
Markedsværdi
57,82 mio. SEK
Aktieomsætning
23,97 t SEK
Volumen
8,3 t
Finanskalender
Delårsrapport
23.08.2024
Delårsrapport
08.11.2024
Årsrapport
14.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Orpahazyme AS | 10,0 % | 10,0 % |
Jan Ivar Nordqvist | 9,5 % | 9,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Västra Hamnen publishes initial analysis of CombiGene
CombiGene enters into a license agreement with Spark for the epilepsy project CG01
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools